Pidotimod: The state of art

Clinical and Molecular Allergy

Volumn 13, Issue 1, 2015, Pages

  Ferrario, Beatrice E ^a   Garuti, Silvia ^a   Braido, Fulvio ^a   Canonica, Giorgio W ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

natural immunity; Pidotimod

Indexed keywords

IMMUNOGLOBULIN A; PIDOTIMOD; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ADULT DISEASE; ASTHMA; CHILDHOOD DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INNATE IMMUNITY; LYMPHOCYTE; MORBIDITY; MORTALITY; NONHUMAN; PEAK EXPIRATORY FLOW; PHARMACOLOGY; RECURRENT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; T LYMPHOCYTE; TRACHEA CILIARY CELL; VACCINATION;

EID: 84929452775     PISSN: None     EISSN: 14767961     Source Type: Journal    
DOI: 10.1186/s12948-015-0012-1     Document Type: Review

References (41)

1. Zuccotti GV, Mameli C. Pidotimod: the past and the present. Int J Ped. 2013;39(75):2-3.
2. Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology. 2007;120:435-66.
3. Zuccotti GV, Mameli C, Trabattoni D, Beretta S, Biasin M, Guazzarotti L, et al. Immunomodulating activity of Pidotimod in children with Down Syndrome. J Biol Regul. 2013;27(1):207-12.
4. Schwarze J, Mackenzie KJ. Novel insights into immune and inflammatory responses to respiratory viruses. Thorax. 2013;68:108-10.
5. Giagulli C, Noerder M, Avolio M, Becker PD, Fiorentini S, Guzman CA, et al. Pidotimod promotes functional maturation of dendritic cells and display adjuvant properties at the nasal mucosa level. Int Immunopharmacol. 2009;9:1366-73.
6. Rossi GA, Peri C, Raynal ME, Defilippi A-C, Risso FM, Schenone G, et al. Naturally occurring immune response against bacteria commonly involved in upper respiratory tract infections: analysis of the antigen-specific salivary IgA levels. Immunol Lett. 2003;2003(86):85-91.
7. Wu S, Jiang ZY, Sun YF, Yu B, Chen J, Dai CQ, et al. Microbiota regulates the TLR7 signaling pathway against respiratory tract influenza A virus infection. Curr Microbiol. 2013;67(4):414-22.
8. Carta S, Silvestri M, Rossi G. Modulation of airway epithelial cell functions by Pidotimod: NF-kB cytoplasmatic expression and its nuclear translocation are associated with an increased TLR-2 expression. It J Ped. 2013;39(29):2-9.
9. Fogli M, Caccuri F, Iaria ML, Giagulli C, Corbellini S, Campilongo F, Caruso A, Fiorentini S. The immunomodulatory molecule Pidotimod induces the expression of the NOD-like receptor NLRP12 and attenuates TLR-induced inflammation. Studio Clinico 2014.
10. Zhou Y, Dai Y. Comparison of effects of Pidotimod and spleen aminopeptide on clinical symptoms and Th1/Th2 cytokines in children with RRI. Chin J Bioch Pharm. 2012;33(1):64-9.
11. Licari A, De Amici M, Nigrisoli S, Marseglia A, Caimmi S, Artusio L, et al. Pidotimod may prevent recurrent respiratory infections in children. Minerva Pediatr. 2014;66(5):363-7.
12. La Mantia I, Grillo C, Mattina T, Zaccone P, Xiang M, Di Mauro M, et al. Prophylaxis with the novel immunomodulator Pidotimod reduces the frequency and severity of upper respiratory tract infections in children with Down's Syndrome. J Chemother. 1999;11(2):126-30.
13. Yan Y. Changes of immune function in children with refractory mycoplasma pneumoniae pneumonia and effects of Pidotimod. J Clin Pediatr. 2008;26(7):570-2.
14. Gourgiotis D, Papadopoulos NG, Bossios A, Zamanis P, Saxoni-Papageorgiou P. Immune modulator Pidotimod decreases the in vitro expression of CD30 in peripheral blood mononuclear cells of atopic asthmatic and normal children. J Asthma. 2004;41(3):285-7.
15. Zhigui J, Jiang Z, Liang H, Yang C, Li W, Lin Y. Effect of Pidotimod in preventing the relapse of Henoch-Schonlein purpura and the impact on immune function. Chin Med Herl J 2012; 9 (18).
16. Zheng H, Sheng W. The observation of Pidotimod in preventing the relapse of nephrotic syndrome in 86 cases. Drugs and clinical studies 2009.
17. Di F, Di Filippo S, Varacalli S, Zardo F. Pidotimod nel trattamento delle faringotonsilliti recidivanti. Actamed Drug Rev Spec. 1995;192(96):1-8.
18. Li X, Bai H. Treatment of 30 cases of senile pneumonia with Pidotimod. Clin Pharm 2004; 13 (9).
19. Borghi MO, Fain C, Barcellini W, Del Papa N, La Rosa L, Nicoletti F, et al. Ex vivo effect of Pidotimod on peripheral blood mononuclear cell immune funtions: study of an elderly population. Int J Immunother. 1994;X(1):35-9.
20. Lin D, Xu B. Impact of Pidotimod on local immunity in the genital tract of female patients with non-gonococcal urethritis. Chin J Clin. 2013;7(8):3585-6.
21. Li Y, Dai Y, Deng B, Liang X, Xie Z, Chen H. Effect of Pidotimod on interleukin-13 of patients with recurrent genital herpes. J Hain Med Univ. 2011;17(8):1068-71.
22. Zhang C, Zhang W, Lin H. Effect of Pidotimod on expressions of IL-2 and IL-10 of patients with genital herpes and curative effect observation. Clin J Pharmacoepidemiol. 2010;19(3):126-31.
23. Zhang J, Li Y. Efficacy of ceftriaxone combined with Pidotimod on serofast syphilis. Acta Ac Med Qing Univ 2011; 47 (1).
24. Guerra B, Perino A, Polatti F, Scala M. Pidotimod in the managemente of vulvar papillomatosis: double-blind clinical trial versus placebo. Am J Ther. 1998;5:147-52.
25. Zervoudis S, Iatrakis G, Peitsidis P, Peitsidou A, Papandonopolos L, Nikolopoulou MK, et al. Complementary treatment with oral Pidotimod plus vitamin C after laser vaporization for female geniital warts: a prospective study. J Med Life. 2010;3(3):286-8.
26. Li Y, Cai H, Gu Y, Li Y. Effects of Pidotimod on immune function of patients with chronic hepatitis C. J Lanz Univ 2006; 32 (1).
27. Holt P. Prevention - What is the most promising approach? Ped All Immunol. 2014;25:12-4.
28. Wu Y, Ling J. Observation of impact and efficay of Pidotimod on serum interleukin-4 and gamma-interferon levels in children with asthma. Chin Med Herl J. 2013;10(24):101-5.
29. Jackson DJ, Hartert TV, Martinez FD, Weiss ST, Fahy JV. Asthma: NHLBI workshop oh the primary prevention of chronic lung diseases. Ann ATS. 2014;11(3):139-45.
30. Zhai F, Liu X. The effect of Pidotimod in the prevention and Treatment of Pediatric Bronchial Asthma. Chin J Biochem Pharm. 2011;32(2):151-5.
31. Ma X, Sun X. The effect of Pidotimod on serum IL-4, IFN-gamma and IgE in asthmatic children. Chin J Biochem Pharm. 2011;32(5):400-3.
32. Bisetti G, Ciappi G, Bariffi F, Catena E, Rocco V, Vaccaro L, et al. Evaluation of the efficacy of Pidotimod on the exacerbations in patients affected with chronic bronchitis. Arzneim Forsch Drug Res. 1994;44 II(12):1499-502.
33. Ciaccia A et al. Pidotimod activity against chronic bronchitis exacerbations. Arzneim Forsch Drug Res. 1994;44(II):1516-20.
34. Benetti GP, Illeni MT, Passera A, Bombelli G, Lavecchia G, Uslenghi C. Ex vivo evaluation of Pidotimod activity in patients with chronic obstructive pulmonary disease. Arneim Forsch Drug Res. 1994;44 II(12):1503-5.
35. Chen J, Wang H, Liu Y, Xia C, Qi M. Immunological function of T-lynphocyte in the elderly with chronic obstuctive pulmonary disease during acute exacerbations medication intervention. Chin J Geriatr. 2006;25(6):434-40.
36. Cogo R. Valutazione sperimentale controllata dell'attività di Pidotimod in pazienti affetti da BPCO. Min Pneumol. 2014;53:1-6.
37. Pozzi E, Dolcetti A, Orlandi O, Cirianni C, Moreo G, Piacenza G, et al. Pidotimod in the treatment in patients affected by bacterial exacerbations of chronic bronchitis. Arzneim Forsch Drug Res. 1994;44(II):1495-8.
38. Cogo R, Ramponi A, Monzani G, Uslenghi C, Girardello R. Valutazione dell'attività del Pidotimod sulla secrezione di IgA in pazienti affetti da BPCO. Giorn It Allergol Immunol Clin. 1993;3:253-9.
39. Mailland F, Coppi G, Silingardi S. Pharmacokinetics and oral bioavailability of Pidotimod in humans. Arzneim Forsch Drug Res. 1994;44(II):1465-9.
40. Qi X, Wang L, Zhu J. Water in oil in water double emulsions: an excellent delivey system for improving the oral bioavailability of Pidotimod in rats. J Pharmaceut Sci May. 2011;100(6):2203-11.
41. Adams K, Allen JA, Brooker PC, Henderson L, Jones E, Proudlock RJ, et al. Genotoxicity testing of Pidotimod in vivo and in vitro. Arzneim Forsch Drug Res. 1994;44 II(12):1454-9.